FDA Approves Oral Combination of Decitabine and Cedazuridine Tablets with Venetoclax for Newly Diagnosed AML
esmo - Evidence for efficacy is based on the results from the Study ASTX727-07
AI Summary: The FDA has approved an oral combination (decitabine/cedazuridine plus venetoclax) as a treatment option for newly diagnosed acute myeloid leukemia patients who are older or unfit for intensive therapy. The approval offers an at-home alternative to frequent infusions, potentially reducing clinic visits and improving convenience for a vulnerable population.
- Experts celebrate all-oral AML option online (3)
- FDA approval and ASCERTAIN V trial evidence (3)
- Targeted therapies and regimen optimization in AML (3)
Experts celebrate all-oral AML option online
FDA approval and ASCERTAIN V trial evidence
Targeted therapies and regimen optimization in AML
Related Stories
Bristol Myers Squibb wins first-in-class approval for protein‑degrader myeloma therapy / 19 days
Belzutifan plus pembrolizumab gains approval for adjuvant RCC / 5 wks
FDA greenlights datopotamab deruxtecan for metastatic TNBC / 2 months
FDA approves belzutifan (Welireg) plus pembrolizumab for adjuvant RCC / 2 months
VOLGA Phase III shows survival benefit for bladder cancer neoadjuvant combo / 3 months
FDA expands approval of Lu‑177 radiopharmaceutical for prostate cancer / 26 days
FDA clears Trodelvy alone and with Keytruda for first-line TNBC / 2 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Pfizer, Telemedicine, Long COVID, Health IT and look for the RSS link.
StackHealth Time Machine